Biologics for IBD (Anti-TNF, Vedolizumab, Ustekinumab, Risankizumab, Mirikizumab)
Powerful injection or infusion medications that put inflammatory bowel disease into remission. Each works on a different immune pathway. Game-changing for moderate-to-severe Crohn's and ulcerative colitis.
This article is educational and does not replace your doctor's advice. Seek urgent care for any red-flag symptoms.
Drug class
Biologic monoclonal antibodies (different targets)
Examples
**Anti-TNF**: infliximab (Remicade, biosimilars), adalimumab (Humira, biosimilars), golimumab (Simponi). **Anti-integrin (gut-selective)**: vedolizumab (Entyvio). **Anti-IL12/23**: ustekinumab (Stelara). **Anti-IL23**: risankizumab (Skyrizi), mirikizumab (Omvoh).
How it works
Each biologic targets a different molecule that drives inflammation in IBD. Anti-TNF blocks tumor necrosis factor — a master inflammation signal. Vedolizumab blocks white blood cells from entering the gut specifically. Ustekinumab and risankizumab block specific interleukins (IL-12, IL-23). The right choice depends on disease type, severity, prior treatments, and patient factors.
What it treats
- Moderate-to-severe Crohn's disease
- Moderate-to-severe ulcerative colitis
- Perianal Crohn's fistulas
- Steroid-dependent or steroid-refractory IBD
- Some other autoimmune diseases (psoriasis, rheumatoid arthritis)
How to take it
Infliximab — IV infusion every 8 weeks (after induction). Hospital or infusion clinic.
Adalimumab — subcutaneous injection every 2 weeks at home (auto-injector pen).
Vedolizumab — IV infusion every 8 weeks. Subcutaneous form available.
Ustekinumab — first dose IV, then subcutaneous every 8 weeks.
Risankizumab and mirikizumab — IV induction, then subcutaneous maintenance every 4-8 weeks.
Each has a "loading dose" then maintenance schedule.
Common side effects
- Injection site or infusion reactions
- Headache, fatigue
- Mild upper respiratory infections
- Nausea
Serious side effects — call your doctor
Severe infection (high fever, pneumonia, abscess)
Possible serious infection — see your doctor urgently. Hold biologic.
TB symptoms (cough, weight loss, night sweats)
TB reactivation risk — needs urgent screening.
Viral hepatitis B reactivation
Stop biologic; antiviral treatment.
New skin lesions or unusual lumps
Investigate for skin cancer or lymphoma — small but real risks.
Severe allergic infusion reaction
Emergency.
Interactions
Most biologics: no significant drug-drug interactions. Avoid live vaccines (MMR, varicella, yellow fever, BCG) while on biologics — get them BEFORE starting. Inactivated vaccines (flu, pneumococcal, hepatitis B, COVID) are safe and recommended.
Monitoring
Before starting: TB test (PPD or IGRA), chest X-ray, hepatitis B/C screening, HIV, baseline CBC, liver function. During treatment: periodic CBC, liver tests, calprotectin, drug levels (for some). Annual: skin check, age-appropriate cancer screening.
When and how to stop
Don't stop without doctor — risk of flare and loss of response. May taper after 2-4 years of stable remission in carefully selected patients (with continued maintenance immunomodulator like azathioprine).
Pregnancy & breastfeeding
Most biologics are considered safe in pregnancy. Anti-TNF: continue to maintain remission; some women stop after week 22-24. Vedolizumab and ustekinumab: continue throughout. Live vaccines (BCG, rotavirus) for the BABY: delay 6-12 months after birth. Discuss family planning with your IBD team early.
In the Saudi context
All major biologics for IBD are MOH-approved and available in Saudi Arabia. Insurance plans vary — some require prior authorization. Several Saudi tertiary centers run biologic infusion clinics with home injection support programs.
Questions to ask your doctor
Save this list or print it before your appointment — doctors appreciate prepared patients.
- Which biologic is best for my disease?
- What screening do I need before starting?
- Will I need biologic forever?
- Which vaccines should I get before starting?
Medically reviewed by: SGA Patient Education Panel · Last reviewed 24/04/2026